Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Spontaneous Reduction of Clone Size in Paroxysmal Nocturnal Hemoglobinuria Patients Treated with Eculizumab for Greater Than 12 Months.

Richard Kelly, MBChB, Stephen Richards, PhD, Louise Arnold, BSc, MA, Gemma Valters, BSc, Matthew Cullen, MA, Anita Hill, MBChB, (Hons), PhD, Peter Hillmen, PhD

Blood (2009) 114 (22): 1992.

https://doi.org/10.1182/blood.V114.22.1992.1992

Published: 2009

Journal Articles

The Investigation of HMGA2 Dysregulation and Promoter Mutations in PIG-M in the Molecular Pathogenesis of Paroxysmal Nocturnal Haemoglobinuria (PNH).

Richard J. Kelly, MD, Reuben M. Tooze, PhD, Gina M. Doody, PhD, Stephen J. Richards, PhD, Peter Hillmen, PhD

Blood (2007) 110 (11): 3671.

https://doi.org/10.1182/blood.V110.11.3671.3671

Published: 2007

Journal Articles

High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis.

Anita Hill, MD, Scott A. Reid, PhD, Russell P. Rother, PhD, Mark T. Gladwin, MD, Paul O. Collinson, PhD, David C. Gaze, PhD, Angela Lowe, DCR, Ashley Guthrie, FRCR, Mohan U. Sivananthan, MD, Peter Hillmen, PhD

Blood (2006) 108 (11): 979.

https://doi.org/10.1182/blood.V108.11.979.979

Published: 2006

Journal Articles

The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.

Anita Hill, MD, Philip J. Platts, MRes, Alex Smith, PhD, Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Quentin A. Hill, MD, Eve Roman, PhD, Peter Hillmen, PhD

Blood (2006) 108 (11): 985.

https://doi.org/10.1182/blood.V108.11.985.985

Published: 2006

Journal Articles

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

Anita Hill, MD, Russell P. Rother, PhD, Antonio M. Risitano, PhD, Duncan S. Cole, PhD, Matthew J. Cullen, MSc, Stephen J. Richards, PhD, Carmine Selleri, MD, Patrizia Ricci, BSc, Bruno Rotoli, MD, Lucio Luzzatto, PhD, Peter Hillmen, PhD

Blood (2006) 108 (11): 972.

https://doi.org/10.1182/blood.V108.11.972.972

Published: 2006

Journal Articles

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Sheila J. O’Connor, PhD, Kathryn Turner, MSc, Sharon L. Barrans, PhD, Brad Dickinson, MSc, Andy C. Rawstron, PhD, Hazem Sayala, MD, Paul Moreton, MD, Roger G. Owen, MD, Andrew S. Jack, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 2936.

https://doi.org/10.1182/blood.V106.11.2936.2936

Published: 2005

Journal Articles

Comparison of Oral and Intravenous Fludarabine in the LRF CLL4 Trial.

Peter Hillmen, PhD, Sue Richards, PhD, Daniel Catovsky, MD, UK NCRI CLL Trials Group

Blood (2005) 106 (11): 722.

https://doi.org/10.1182/blood.V106.11.722.722

Published: 2005

Journal Articles

Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Anita Hill, MD, Xunde Wang, PhD, Robert J. Sapsford, MD, Rother P. Russell, PhD, Alison L. Farrell, PGDip, Hilary A. Jessop, Gina M. McGawley, MSc, David L. Oxborough, BHSc, Paul Pleasants, BSc, Stephen J. Richards, PhD, Louise M. Arnold, BSc, David M. Buchanan, MA, Sara Rollinson, PhD, Mark T. Gladwin, MD, Peter Hillmen, PhD

Blood (2005) 106 (11): 1046.

https://doi.org/10.1182/blood.V106.11.1046.1046

Published: 2005

Journal Articles

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Anita J. Dickinson, MSc, Anita Hill, MD, David Buchanon, MA, Louise Arnold, BSc, Modupe Elebute, MD, Russell P. Rother, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 1047.

https://doi.org/10.1182/blood.V106.11.1047.1047

Published: 2005

Journal Articles

Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.

Anita Hill, MD, Dupe Elebute, MD, Judith C. Marsh, MD, Stephen J. Richards, PhD, Bruce McNutt, MD, Beth E. Petro, BS, Russell P. Rother, PhD, Peter Hillmen, PhD

Blood (2004) 104 (11): 2823.

https://doi.org/10.1182/blood.V104.11.2823.2823

Published: 2004

Journal Articles

Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria.

Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Anita J. Dickinson, MSc, Claire Hall, MD, Anita Hill, MD, Peter Hillmen, PhD

Blood (2004) 104 (11): 172.

https://doi.org/10.1182/blood.V104.11.172.172

Published: 2004

NARROW

A Spontaneous Reduction of Clone Size in Paroxysmal Nocturnal Hemoglobinuria Patients Treated with Eculizumab for Greater Than 12 Months.

The Investigation of HMGA2 Dysregulation and Promoter Mutations in PIG-M in the Molecular Pathogenesis of Paroxysmal Nocturnal Haemoglobinuria (PNH).

High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis.

The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Comparison of Oral and Intravenous Fludarabine in the LRF CLL4 Trial.

Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria.

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.

Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only